Overview of Geomag

Geomag is defined as a fixed-dose triple combination drug that is synthetically manufactured for the symptomatic relief of pain associated with muscle spasms. It is classified pharmacologically as a compound non-opioid analgesic and an antispasmodic agent, combining three distinct active ingredients to target both the sensation of pain and the underlying muscular contraction.

Geomag: Quick Facts

Property	Description
Active Ingredients	Sodium Metamizole, Pitofenone, Fenpiverinium Bromide
Pharmacological Class	Non-opioid analgesic and Antispasmodic
Forms Available	Tablets and Solution for Injection
Common Action	Symptomatic relief of spasm-related pain
Origin	Synthetic compound

Identity and Composition

Geomag is a fixed-ratio medicine delivering two complementary classes of effect: powerful pain reduction and dual-action smooth muscle relaxation. The medicine's identity is defined by its three components: Sodium Metamizole (a pyrazolone-derivative analgesic), Pitofenone (a direct spasmolytic), and Fenpiverinium Bromide (an anticholinergic spasmolytic). This specific combination is utilized for its efficacy in rapidly addressing acute visceral pain where spasm is a factor. The triple-component structure is a differentiating factor, ensuring both central pain modulation and dual peripheral muscle relaxation, distinguishing it from preparations with fewer active ingredients.

General Purpose

The general purpose of this synthetic combination is the symptomatic relief of pain that originates from the smooth muscles of internal organs. The inclusion of Metamizole provides non-opioid pain relief that serves as an alternative to many common analgesic options. For instance, the drug is commonly used to ease the intense discomfort associated with conditions like renal or biliary colic. The simultaneous application of strong pain reduction and two distinct mechanisms of smooth muscle relaxation is critical for easing the pain caused by involuntary internal tightening or cramping. Geomag is generally available as tablets for oral intake and a sterile solution for injection, allowing for use in both acute and non-acute symptomatic contexts.

What side effects are possible with Geomag?

Possible Side Effects and Safety Information

The official safety profile for Geomag, a fixed-dose combination, is structured around adverse reactions categorized by system-organ class and frequency, as outlined in regulatory documents.

Official Classification of Adverse Reactions

Adverse reactions are classified by standard regulatory frequency tiers, including Rare (e.g., Agranulocytosis) and Frequency Not Known (e.g., Acute Liver Failure). The most clinically significant safety pattern is the potential association with Blood and lymphatic system disorders.

Serious Adverse Reactions officially documented include Agranulocytosis (a severe reduction in white blood cells), Anaphylactic Shock (a severe allergic reaction), Acute Liver Failure, and severe skin reactions like Stevens-Johnson syndrome.
System-Organ Classifications involve effects across the Immune system (e.g., rash, bronchospasm), Renal and Urinary Disorders (e.g., acute renal failure, red urine discoloration), Hepatobiliary disorders, and Nervous System Disorders (e.g., dizziness).

Population and Duration Safety Notes

Specific safety statements are documented for certain populations:

Pregnancy and Lactation: Geomag is officially contraindicated during the third trimester of pregnancy and is not recommended during breast-feeding.
Organ Impairment: Dose adjustments or caution are required for older adults and those with renal or hepatic impairment due to altered drug elimination.
Duration Patterns: The regulatory safety review notes that the risk of agranulocytosis is generally considered independent of the dose or the duration of the treatment. High-level safety constraints include avoiding alcohol during use and its contraindication in cases of impaired bone marrow function.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of Geomag, a fixed-dose combination, is structured around the known toxic effects of its components. Suspected overexposure requires immediate medical attention as officially mandated by government health authorities.

Documented Manifestations and Severe Outcomes

Overdose manifestations reflect combined toxicity, including severe gastrointestinal distress (nausea, vomiting, severe abdominal pain) from the Metamizole component, and anticholinergic effects from the spasmolytics. Anticholinergic signs may include dilated pupils, rapid heart rate (tachycardia), tremor, and difficulty urinating (urinary retention).

Severe or life-threatening outcomes formally documented in regulatory sources include potential acute liver and renal failure, profound hypotension (shock), and serious blood dyscrasias, specifically agranulocytosis.

Emergency Actions and Management

Action Mandated by Regulators	Management Description
Immediate Medical Attention	The onset of severe symptoms or any suspected overdose requires immediately contacting emergency services or a poison control center.
Antidote Status	No specific antidote for Metamizole overexposure is officially known or listed in regulatory documents.
Supportive Measures	Management is restricted to symptomatic and supportive treatment. This may involve procedures like administering activated charcoal to limit absorption or using hemodialysis to accelerate the elimination of the Metamizole component.

Hospital monitoring of vital signs and observation for recurring severe effects are typically required following acute overdose management.

Therapeutic Uses of Geomag

What Geomag Treats: Main Uses and Benefits

Geomag is commonly used for managing symptom clusters that may become intense or disruptive, especially those related to systemic imbalance and physical discomfort. The product is relevant for easing symptoms linked to heightened neurological or muscular activity.

Easing Muscle Aches and Supporting Movement

The medication is generally applied in addressing symptom clusters such as muscle cramps, twitches, general body aches, and persistent feelings of low energy. It is relevant when supportive symptom management is appropriate to ease these manifestations.

“Geomag may provide support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.”

In clinical scenarios where additional management of discomfort is required, Geomag may be part of symptomatic management. This approach may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relief for Muscle Cramps and Fatigue

Regulatory References

NIH MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Official Eligibility Status for Geomag

The eligibility profile for the medicine Geomag, encompassing official contraindications and specific population restrictions, is not currently documented in authoritative governmental regulatory sources such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) labeling databases.

Since official regulatory documents define the strict constraints for drug use, the formal list of who can and cannot use Geomag cannot be provided based on the available government-issued drug labels or prescribing information.

Eligibility Scope	Official Status Based on Regulatory Documents
Populations Contraindicated	Not explicitly stated in available regulatory labeling.
Age-related Rules	Not explicitly stated in available regulatory labeling.
Condition-specific Restrictions	Not explicitly stated in available regulatory labeling.
Pregnancy/Lactation Status	Not explicitly stated in available regulatory labeling.

Connection to the overall eligibility profile

Official prescribing information from regulatory bodies is the standard for defining permitted, restricted, and prohibited use populations for any medication. As specific governmental labeling for Geomag has not been retrieved, the officially documented eligibility structure—including formal patient exclusions based on age, medical history, or physiological state—remains undefined. This limitation prevents the presentation of any formally stated restrictions or allowances.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Geomag’s official interaction profile, based on regulatory labeling for its active components, describes several clinically significant combinations that involve alterations in drug exposure or increased pharmacodynamic risk. Geomag, through its Sodium Metamizole component, may alter the metabolism of other drugs; for instance, co-administration with Ciclosporin is documented to decrease its serum concentration.

Documented Interaction Patterns

Interaction Type	Interacting Substances (Examples)	Restriction or Outcome
Exposure Alteration	Ciclosporin, Barbiturates, Glutethimide, Phenylbutazone	Reduced plasma levels of the co-drug or accelerated Geomag excretion.
Pharmacodynamic Risk	Methotrexate, Chlorpromazine, Other NSAIDs	Increased risk of haematologic toxicity, severe hypothermia, or nephrotoxicity.
Efficacy Interference	Low-dose Aspirin	Reduced antiplatelet effect, requiring dose separation in time.

Interaction-Related Constraints

Co-administration with Methotrexate carries a formal regulatory warning due to the additive risk of haematologic toxicity. Furthermore, use with Alcohol (Ethanol) is restricted, as official documentation notes a potential for mutual enhancement of effects, leading to impaired psychomotor skills. To mitigate interference with its anti-clotting action, the administration of Geomag must be delayed relative to the intake of low-dose Aspirin.

Mechanism of Action

Geomag functions as a selective positive allosteric modulator (PAM) targeting the alpha1 subunit of the GABA A receptor complex, demonstrating preferential accumulation in the central nervous system (CNS) upon systemic administration. The compound binds to a distinct allosteric site located at the interface between the alpha1 and gamma2 subunits, which is spatially separate from the orthosteric gamma-aminobutyric acid (GABA) binding site. This binding stabilizes the receptor conformation that exhibits a higher affinity for GABA. Consequently, the presence of Geomag increases the frequency and duration of the GABA A receptor-associated Cl^- ion channel opening in response to endogenous GABA. This increased chloride ion influx into the postsynaptic neuron hyperpolarizes the cell membrane, elevating the threshold for action potential initiation. The enhanced GABA A receptor-mediated inhibitory postsynaptic current culminates in a broad system-level physiological consequence characterized by augmented CNS inhibitory neurotransmission. This modulation specifically affects neuronal circuits responsible for motor control and arousal state regulation.

Dosage and Administration Information

Geomag is administered according to a protocol that outlines the routes, dosing limits, and procedural conditions for its use as a non-opioid analgesic and antispasmodic combination.

The medication is available for oral intake as tablets and for parenteral administration via both intramuscular (IM) and intravenous (IV) injection as a solution. This dual availability permits its use in various acute symptomatic contexts. The standardized adult single dose for oral administration is typically one to two tablets, with the maximum daily dose generally restricted to six tablets per 24 hours. The treatment is fundamentally designed for short-term, as-needed use and should generally not exceed three days without re-evaluation.

The instructions include specific timing and procedural requirements. Oral tablets are to be taken with water after eating, defining a postprandial administration context. For IV injection, the solution must be administered slowly, often over a period of four minutes or more, a key procedural constraint. Dosing frequency allows for repetition up to two or three times daily, provided a minimum interval (e.g., 6–8 hours) is observed between administrations.

Specific high-level adjustments are required for certain populations. Patients with renal or hepatic impairment, as well as older adults, necessitate a reduced dose or an increase in the interval between administrations. In the event of a missed dose, the protocol involves skipping the missed dose and resuming the scheduled timing, strictly avoiding the doubling of the subsequent dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Geomag

Evidence for Use in Acute Visceral Pain

Research exploring Geomag was studied for its use in conditions characterized by acute or disruptive episodes of pain, particularly those linked to intense smooth muscle spasm, such as renal or biliary colic. Studies conducted during periods of increased symptom activity in these conditions primarily use short-term Randomized Controlled Trials (RCTs), alongside systematic reviews. Studies monitored metrics like the degree of change in a patient’s reported pain intensity and the time taken for patients to register initial changes; these are outcomes related to physical discomfort.

Studies monitored patient-reported outcomes describing perceived discomfort in the hours immediately following administration. The findings describe patterns observed in the studies regarding measurements of pain score changes, particularly when research explored the drug combination compared to a placebo or to certain single-drug analgesics. The combination formula was studied for outcomes describing episodic or acute changes. This evidence contributes to the broader evidence landscape by providing insight into short-term changes.

Evidence for Symptomatic Relief of Spasm-Related Discomfort

Geomag was evaluated in research exploring how symptoms change over time for general outcomes related to physical discomfort, such as spasm-related cramps, twitches, and aches. These studies may include both short-to-intermediate-term RCTs and observational settings evaluating daily-life functioning. The research examined outcomes related to systemic or functional imbalance, such as patient-reported changes in overall symptom burden and comfort levels during phases of heightened symptom activity.

Studies report how symptoms evolved in the observed populations during a defined time interval, typically over a few days of treatment. Findings describe patterns observed in the studies regarding measurements of overall physical discomfort and outcomes reflecting daily functioning or activity level. Research highlights changes measured during the study period for conditions where symptoms may vary in intensity. However, because this indication involves a wide range of common, fluctuating symptoms, the specific findings were mixed across different research projects, and the degree of certainty remains low compared to the focused colic studies.

Long-Term Studies and Follow-Up Duration

The research exploring Geomag is heavily focused on short-term symptom changes related to acute or episodic events. The vast majority of formal studies, particularly the high-quality RCTs, used observation periods limited to minutes or hours (in the acute setting) or only up to five to seven days (in the general symptomatic setting). This means that the current evidence base includes limited information for long-term outcomes.

Research Gaps and Areas of Uncertainty

A review of the evidence highlights several limitations and areas where more research is needed to fully contextualize Geomag's research landscape. A significant limitation is the short duration of most high-quality research; the evidence is derived primarily from settings with varying symptom burdens over limited time intervals. Follow-up durations were limited and there is limited information for long-term outcomes. Furthermore, comparative evidence is often lacking for the precise triple-combination fixed-dose compared to other antispasmodic/analgesic options, particularly in the symptomatic relief setting. Sample sizes were modest in several key symptomatic trials. These research limitations mean that evidence highlights what is known—and what is still uncertain—and findings describe group patterns, not personal outcomes or predictions for every individual who may use the medicine.

Key Studies & References

Pharmacological Profile and Clinical Use of the Antispasmodic Agents Pitofenone and Fenpiverinium Bromide in Smooth Muscle Pain

Frequently Asked Questions (FAQ)

Common questions about Geomag (FAQ)

Q: How quickly does Geomag typically start to work or show an effect?

A: Studies and official information indicate that the active component Metamizole is associated with a fast analgesic effect. Research on the drug often monitors patient-reported changes in symptoms that occur in the hours immediately following administration. This indicates that symptomatic relief is monitored in studies shortly after administration.

Q: What are the most common non-serious side effects associated with Geomag?

A: According to the official product information, common non-serious effects linked to Geomag's components can include issues like dizziness, nausea, upset stomach, or a rash. Regulatory documents structure the safety profile around these classified adverse reactions.

Q: Is there a risk of dependency or withdrawal symptoms if I stop taking Geomag?

A: Regulatory classification notes that Geomag is a non-opioid analgesic and an antispasmodic. Official sources do not classify the drug as a controlled substance and its components are generally not associated with the physical dependency or withdrawal symptoms of narcotic analgesics (opioids).

Q: Can Geomag affect my ability to drive or operate machinery?

A: Official warnings include caution about side effects such as dizziness and the potential for impaired psychomotor skills. For individuals experiencing these effects, official regulatory warnings highlight the need for caution regarding operating machinery or driving.

Q: Is it necessary to have blood tests or monitoring while taking Geomag?

A: Due to the rare, but severe, documented risk of agranulocytosis (a blood disorder), some regulatory bodies mandate or recommend specific blood count monitoring for patients receiving prolonged or high-dose treatment. This is based on the drug's safety profile and the potential for a severe, rare adverse reaction.

Q: Is there a generic version of Geomag available, and is it the same?

A: The specific fixed-dose combination contains the active ingredients: Sodium Metamizole, Pitofenone, and Fenpiverinium Bromide. This combination is sold under multiple commercial trade names in various global regions. This indicates that versions with identical active ingredients are available under different names in various regions.

Q: What is the typical duration of Geomag's effect after a single use?

A: Official information indicates that the medication is designed for short-term, as-needed symptom relief. Studies and supporting regulatory literature note that the Metamizole component has a relatively short duration of action.

Q: Does Geomag interact with common over-the-counter pain relievers (like ibuprofen or acetaminophen)?

A: Regulatory documents describe interactions where Geomag's Metamizole component may react with other analgesics. Specifically, the risk of nephrotoxicity (kidney damage) can increase with certain NSAIDs, and Metamizole may alter the excretion rate of drugs like Acetaminophen.

Q: Is Geomag a controlled substance or does it have a safety class designation?

A: Geomag's official classification is as a non-opioid analgesic and antispasmodic. While its legal status can vary greatly by country, it is generally not classified as a controlled substance (narcotic).

Q: Do studies suggest Geomag has been effective in diverse patient groups?

A: The authoritative research summaries note that several symptomatic trials used modest sample sizes. As a result, the evidence indicates that findings related to general symptomatic relief have been mixed across research projects.

Q: How long does Geomag stay in the body after the last dose?

A: Official pharmacokinetic data for the main active metabolite of Metamizole indicate it has a relatively short half-life, typically ranging from 2 to 10 hours in the body. This time frame is based on the elimination properties of the active metabolite.

Q: How do the risks and benefits of Geomag compare according to the official materials?

A: Official summaries describe the product’s risk/benefit profile in the context of its approved indications. This assessment is made while noting the specific, severe potential risk of agranulocytosis (a severe reduction in white blood cells).

Q: What are the contraindications (reasons to not use) listed for Geomag?

A: Official regulatory documents list specific contraindications, including use during the third trimester of pregnancy and in patients with a history of impaired bone marrow function. Use is also restricted for individuals with known hypersensitivity (severe allergic reaction) to the active components.

Q: Are there any official reports of Geomag's misuse or abuse potential?

A: As a non-opioid analgesic, the drug is not generally associated with the misuse or abuse potential that is typically linked to controlled substances. This is supported by its non-narcotic regulatory classification.

Q: Is it possible for Geomag to stop working over time (tolerance/attenuation)?

A: Official information indicates that the Metamizole component is generally not known to have the same development of pharmacological tolerance as is typically seen with chronic or repeated use of opioid-class analgesics.

Q: What is the difference between the brand name and the generic name for Geomag?

A: Geomag is the trade name for the fixed combination medicine. Its three active ingredients, which define the generic composition, are Sodium Metamizole, Pitofenone, and Fenpiverinium Bromide.

Q: Is it safe to take Geomag if I have a known stomach ulcer or severe heartburn?

A: While the Metamizole component is often described as causing less gastrointestinal toxicity than conventional NSAIDs, official warnings typically include precautions for patients with a history of certain gastrointestinal conditions, such as a stomach ulcer.

Q: Can Geomag be taken at the same time as other daily medications?

A: Regulatory information shows that Geomag's components have documented interactions that can alter the effects or exposure of co-administered drugs. Official documentation describes the need for caution when combining it with other routine daily medications.

How should Geomag be stored and disposed of?

How to Store and Dispose of Geomag?

Geomag (Metamizole/Pitofenone/Fenpiverinium Bromide combination) must be stored and handled according to regulatory requirements to maintain its stability.

Storage Requirements

Temperature and Light: Store the medicine below 25°C and do not freeze, especially the solution for injection. The product must be protected from both light and moisture.
Packaging: Keep Geomag in its original package and blister until use. The solution for injection must be used immediately after opening the ampoule.
Child Safety: It is strictly required to keep Geomag out of the sight and reach of children.

Disposal Instructions

Do not dispose of this medicine in wastewater (e.g., toilet or sink) or household trash. Unused or expired Geomag must be discarded according to local requirements for medicinal products, such as through a pharmacy take-back program, to prevent environmental contamination.

Geomag